The noble Lord referred to me-too drugs. I hope that he agrees that it is important to recognise that such drugs have often been developed in parallel. They do not take a molecule and just copy it; they develop a new molecule or delivery system, often to minimise side-effects and to maximise efficacy. But they also have a production cost behind them. They are not just copies of something previously produced and marketed differently; they have innovation behind them as well.
Health Service Medical Supplies (Costs) Bill
Proceeding contribution from
Baroness Finlay of Llandaff
(Crossbench)
in the House of Lords on Monday, 23 January 2017.
It occurred during Debate on bills
and
Committee proceeding on Health Service Medical Supplies (Costs) Bill.
About this proceeding contribution
Reference
778 c42GC Session
2016-17Chamber / Committee
House of Lords Grand CommitteeSubjects
Librarians' tools
Timestamp
2021-10-12 15:12:03 +0100
URI
http://hansard.intranet.data.parliament.uk/Lords/2017-01-23/1701242000050
In Indexing
http://indexing.parliament.uk/Content/Edit/1?uri=http://hansard.intranet.data.parliament.uk/Lords/2017-01-23/1701242000050
In Solr
https://search.parliament.uk/claw/solr/?id=http://hansard.intranet.data.parliament.uk/Lords/2017-01-23/1701242000050